Liver Diseases
Welcome,         Profile    Billing    Logout  
 309 Companies   473 Products   473 Products   224 Mechanisms of Action   25 Trials   4900 News 


«12345678910111213...9899»
  • ||||||||||  Trial completion:  HepART-RCT: Hepatitis C Alcohol Reduction Treatment (clinicaltrials.gov) -  Oct 18, 2018   
    P=N/A,  N=182, Completed, 
    Phase classification: P1 --> P1b Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Phase classification, Enrollment change:  Novel Therapies for Metabolic Complications of Lipodystrophies (clinicaltrials.gov) -  Oct 16, 2018   
    P=N/A,  N=4, Completed, 
    Enrolling by invitation --> Completed | N=60 --> 18 Recruiting --> Completed | Phase classification: P2/3 --> PN/A | N=72 --> 4
  • ||||||||||  Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Compassionate Use of Omegaven® for the Treatment of Intestinal Failure Associated Liver Disease in Children (clinicaltrials.gov) -  Oct 15, 2018   
    P2,  N=6, Completed, 
    Recruiting --> Completed | Phase classification: P2/3 --> PN/A | N=72 --> 4 Enrolling by invitation --> Completed | N=20 --> 6 | Trial completion date: Jan 2020 --> Sep 2018 | Trial primary completion date: Jan 2020 --> Nov 2017
  • ||||||||||  evacetrapib (LY2484595) / Eli Lilly
    Enrollment change:  A Study of Evacetrapib (LY2484595) in Participants With Hepatic (Liver) Impairment (clinicaltrials.gov) -  Oct 12, 2018   
    P1,  N=32, Completed, 
    Enrolling by invitation --> Completed | N=20 --> 6 | Trial completion date: Jan 2020 --> Sep 2018 | Trial primary completion date: Jan 2020 --> Nov 2017 N=48 --> 32
  • ||||||||||  Trial completion, Trial completion date:  Early Intervention and Prevention of Non-Alcoholic Fatty Liver Disease in Adolescents (clinicaltrials.gov) -  Oct 12, 2018   
    P=N/A,  N=28, Completed, 
    Recruiting --> Completed | Trial completion date: Sep 2014 --> Nov 2015 | Trial primary completion date: Dec 2013 --> Nov 2015 Active, not recruiting --> Completed | Trial completion date: Jun 2017 --> Oct 2017
  • ||||||||||  sterile N-Acetylcysteine / Generic mfg., acetylcysteine solution / Generic mfg.
    Trial completion date, Trial primary completion date:  NAC in TB DIH: A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis (clinicaltrials.gov) -  Oct 11, 2018   
    P2/3,  N=100, Recruiting, 
    Recruiting --> Completed | Trial completion date: Dec 2011 --> Nov 2015 | Trial primary completion date: Dec 2011 --> Nov 2015 Trial completion date: Dec 2018 --> Aug 2019 | Trial primary completion date: Jun 2018 --> Mar 2019
  • ||||||||||  Inlyta (axitinib) / Pfizer
    Trial completion, Metastases:  Axitinib For The Treatment Of Advanced Hepatocellular Carcinoma (clinicaltrials.gov) -  Oct 10, 2018   
    P2,  N=224, Completed, 
    Trial completion date: Dec 2018 --> Aug 2019 | Trial primary completion date: Jun 2018 --> Mar 2019 Terminated --> Completed
  • ||||||||||  TT-034 / Benitec
    Trial completion date, Trial termination, Trial primary completion date:  Long-Term Follow-Up Safety Monitoring of Patients Dosed in the First-in-Man Phase I/II Study of TT-034. (clinicaltrials.gov) -  Sep 26, 2018   
    P1/2,  N=9, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: May 2019 --> May 2018 Trial completion date: Nov 2022 --> Sep 2018 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2022 --> Sep 2018; Long term safety follow-up no longer required
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Transplant Patient Registry of Liver, Kidney and/or Pancreas (clinicaltrials.gov) -  Sep 26, 2018   
    P=N/A,  N=13767, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Jan 2025 --> Aug 2018 | Trial primary completion date: Jan 2025 --> Aug 2018
  • ||||||||||  sorafenib / Generic mfg.
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) -  Sep 11, 2018   
    P4,  N=180, Completed, 
    Trial completion date: Aug 2017 --> Dec 2018 Recruiting --> Completed | Trial completion date: Jan 2017 --> Jan 2018 | Trial primary completion date: Dec 2016 --> Jun 2017
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Non-invasive Diagnosis of Portal Hypertension With Acoustic Radiation Force Impulse (ARFI) (clinicaltrials.gov) -  Sep 6, 2018   
    P=N/A,  N=500, Completed, 
    Suspended --> Completed | N=25 --> 13 Recruiting --> Completed | N=75 --> 500 | Trial completion date: Jun 2018 --> Sep 2018 | Trial primary completion date: Jun 2018 --> Sep 2018
  • ||||||||||  ENMD-2076 / CASI
    Trial completion, Trial completion date, Trial primary completion date, Metastases:  A Multi-center, Open-label Study of Oral ENMD-2076 for the Treatment of Patients With Advanced Fibrolamellar Carcinoma (clinicaltrials.gov) -  Sep 6, 2018   
    P2,  N=37, Completed, 
    Recruiting --> Completed | N=75 --> 500 | Trial completion date: Jun 2018 --> Sep 2018 | Trial primary completion date: Jun 2018 --> Sep 2018 Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Jun 2018 | Trial primary completion date: Dec 2017 --> Jun 2018
  • ||||||||||  Trial primary completion date:  Gilead Sustained Virologic Response (SVR) Registry (clinicaltrials.gov) -  Sep 1, 2018   
    P=N/A,  N=6625, Completed, 
    N=72 --> 21 | Trial completion date: Aug 2017 --> Oct 2016 | Trial primary completion date: Aug 2017 --> Oct 2016 Trial primary completion date: Nov 2017 --> Mar 2017
  • ||||||||||  Invanz (ertapenem) / Merck (MSD)
    Trial completion, Phase classification, Trial completion date, Head-to-Head:  Antibiotics for Klebsiella Liver Abscess Study (clinicaltrials.gov) -  Aug 27, 2018   
    P4,  N=152, Completed, 
    Recruiting --> Completed Recruiting --> Completed | Phase classification: PN/A --> P4 | Trial completion date: Apr 2018 --> Jan 2018
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Hypofractionated Proton Beam Radiotherapy for Hepatocellular Carcinoma (clinicaltrials.gov) -  Aug 23, 2018   
    P2,  N=112, Completed, 
    Recruiting --> Completed | Phase classification: PN/A --> P4 | Trial completion date: Apr 2018 --> Jan 2018 Recruiting --> Completed | Trial completion date: Apr 2016 --> Apr 2017 | Trial primary completion date: Apr 2016 --> Apr 2017
  • ||||||||||  Hecolin (recombinant hepatitis E vaccine) / Wantai BioPharm
    Trial completion, Trial completion date, Trial primary completion date:  Phase Ⅳ Clinical Trial of Recombinant Hepatitis E Vaccine（Hecolin®） (clinicaltrials.gov) -  Aug 17, 2018   
    P4,  N=601, Completed, 
    Recruiting --> Completed | Trial completion date: Apr 2016 --> Apr 2017 | Trial primary completion date: Apr 2016 --> Apr 2017 Recruiting --> Completed | Trial completion date: Feb 2015 --> Dec 2015 | Trial primary completion date: Dec 2014 --> Dec 2015
  • ||||||||||  Zadaxin (thymalfasin) / SciClone
    Trial completion, Trial completion date, Trial primary completion date:  Optimized Treatment and Regression of HBV-induced Compensated Liver Cirrhosis (clinicaltrials.gov) -  Jul 27, 2018   
    P4,  N=606, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Dec 2018 --> Dec 2016 | Trial primary completion date: Dec 2018 --> Dec 2016
  • ||||||||||  Pegasys (pegylated interferon ? -2a) / Roche
    Trial completion, Trial completion date:  Optimized Treatment and Regression of HBV-induced Liver Fibrosis (clinicaltrials.gov) -  Jul 27, 2018   
    P4,  N=400, Completed, 
    Recruiting --> Completed | Trial completion date: Dec 2018 --> Dec 2016 | Trial primary completion date: Dec 2018 --> Dec 2016 Recruiting --> Completed | Trial completion date: Dec 2018 --> Dec 2016
  • ||||||||||  folate-tubulysin (EC1456) / Novartis
    Trial completion date, Metastases:  Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Jul 24, 2018   
    P1,  N=93, Active, not recruiting, 
    Recruiting --> Completed | Trial completion date: Dec 2018 --> Dec 2016 Trial completion date: Apr 2018 --> Jul 2018
  • ||||||||||  Biomarker, Trial completion, Enrollment change:  Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases (clinicaltrials.gov) -  Jul 19, 2018   
    P=N/A,  N=17, Completed, 
    Trial completion date: Apr 2018 --> Jul 2018 Recruiting --> Completed | N=500 --> 17